A株自社株買いが加速 京東方A、興斉眼薬など主力銘柄が相次ぎ進捗発表

BOE Technology repurchased 500 million yuan of A-shares and 393 million Hong Kong dollars of B-shares, reaching the lower limit of its buyback plan.

Shenyang Xingqi Pharmaceutical completed its 80-100 million yuan buyback plan in about a week, with payment reaching 100 million yuan as of August 4.

Hengrui Medicine has cumulatively paid 853 million yuan for buybacks as of July 31, indicating strong capital return to shareholders.

Topchoice Medical's buyback amount reached 88.75 million yuan, approaching 90% of its 100 million yuan plan cap, showing active capital return.